Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Henry

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|May 13, 2014
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infectionEleanor M P Wilson, Amrit Singh, Katherine Huppler Hullsiek, et al.
AIDS Research and Human Retroviruses|October 13, 2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087Judith A Aberg, Robert A Zackin, Susan W Brobst, et al.
AIDS Research and Human Retroviruses|September 15, 2015
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral TherapyGerome V Escota, Kristin Mondy, Tim Bush, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
Biochemical Pharmacology|July 24, 2017
Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogsDanielle Krout, Akula Bala Pramod, Rejwi Acharya Dahal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2011
Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohortJason V Baker, W Keith Henry, Pragna Patel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
Infection Control and Hospital Epidemiology|February 27, 2003
A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993-1995Francisco Alvarado-Ramy, Elise M Beltrami, Louise J Short, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|May 13, 2014
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infectionEleanor M P Wilson, Amrit Singh, Katherine Huppler Hullsiek, et al.
AIDS Research and Human Retroviruses|October 13, 2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087Judith A Aberg, Robert A Zackin, Susan W Brobst, et al.
AIDS Research and Human Retroviruses|September 15, 2015
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral TherapyGerome V Escota, Kristin Mondy, Tim Bush, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
Biochemical Pharmacology|July 24, 2017
Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogsDanielle Krout, Akula Bala Pramod, Rejwi Acharya Dahal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2011
Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohortJason V Baker, W Keith Henry, Pragna Patel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
Infection Control and Hospital Epidemiology|February 27, 2003
A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993-1995Francisco Alvarado-Ramy, Elise M Beltrami, Louise J Short, et al.
Pageof 14